On Monday, prices of oil gained, and U.S. stock market drowned.
The Dow Jones Industrial Average DJIA, -0.53% tumbled by triple digits at session lows, but finished with a loss of 95.08 points, or 0.5%, at 17,729.21, with 26 of its 30 components closing lower.
During Monday’s trade:
- Atossa Genetics, Inc. (NASDAQ:ATOS), was the top gainer and the most volatile stock of the biotech sector, and added 27.73% to the share, while it remained 11.57% volatile for the week and 8.87% for the month.
- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), was among the top loser of the sector, losing -5.08% from the share.
- Opko Health Inc (NYSE:OPK), hits new 52-week high of $14.59, and closed at $14.21.
- Atossa Genetics, Inc. (NASDAQ:ATOS), remained the most active stock, attaining volume of $9,368,638.
- Keryx Biopharmaceuticals (NASDAQ:KERX), hits new 52-week low of $10.85, and settled at $10.87.
- Achillion Pharmaceuticals, Inc (NASDAQ:ACHN), showed an unusual incline of volume 23.81M, as compared to its average volume of 5.90M for the last trading session.
- CVS Health Corporation, (NYSE:CVS), will release their earning report, before the market open today.
Details about some major gainers from healthcare sector, during Monday’s trade are described below:
In healthcare sector, Atossa Genetics, Inc. (NASDAQ:ATOS), was among the top gainer category for Monday’s trade, with shares boost of 27.73% and led the share to close at $1.52, as the Breast Care Company, has signed an contract with Thermo Fisher Scientific for distribution of Atossa’s FullCYTE Breast Aspirator device in the United States through the Fisher HealthCare channel. Atossa’s FullCYTE Breast Aspirator is used by physicians and nurses to collect nipple aspirate fluid from a patient’s breasts for cytological analysis.
With recent incline, the year-to-date (YTD) performance reflected a 6.29% incline above last year. During the past month the stock gained 26.67%, bringing three-month performance to 50.50% and six-month performance to -11.63%.
Atossa Genetics, Inc. (NASDAQ:ATOS), is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its partner, The National Reference Laboratory for Breast Health, Inc.
Shares of EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), jumped nearly 15.26% to close at $5.59, after a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, declared that the Company is planned to present a corporate overview at the Leerink Global Healthcare Conference in New York City on Thursday, February 12, 2015 at 11:35 a.m. Eastern Time.
With recent incline, the year-to-date (YTD) performance reflected a -1.41% decline below last year. During the past month the stock lose -30.12%, bringing three-month performance to 16.46% and six-month performance to -29.69%. For this company, beta value at 1.74 represents it is more volatile to the shift in the market.
EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), is global biosimilar company focused on improving patient access to important medicines. EPIRUS’ operationally synergistic pipeline of biosimilar product candidates comprises BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab).
Coherus Biosciences, Inc. (NASDAQ:CHRS), surged 12.91% to close at $32.36, hitting new 52-week high of $32.71, following the news that a late-stage clinical biologics platform company focused on the global biosimilar market, declared that it will take part in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 at 1:50 pm ET in New York City.
With recent incline, the year-to-date (YTD) performance reflected a 98.28% incline above last year. During the past month the stock gained 51.78%.
Coherus Biosciences, Inc. (NASDAQ:CHRS), a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide.
Shares of the Avalanche Biotechnologies, Inc. (NASDAQ:AAVL), gained 8.93% & closed at $36.24. The stock volatility for the week is 9.02%, while for the month remained 9.40%.
With recent incline, the year-to-date (YTD) performance reflected a -32.89% decline below last year. During the past month the stock lose -38.75%, bringing three-month performance to 4.29% and six-month performance to 53.95%.
Avalanche Biotechnologies, Inc. (NASDAQ:AAVL), a clinical-stage biotechnology company, focuses on discovering and developing novel gene therapies for the treatment of ophthalmic diseases based on its Ocular BioFactory platform.
Lannett Company, Inc. (NYSE:LCI), mounted 6.35% to close at $55.09, after Lannett, declared financial results for its fiscal 2015 second quarter ended December 31, 2014. For the fiscal 2015 second quarter, net sales rose 71% to $114.8 million from $67.3 million in last year’s second quarter. Gross profit doubled to $87.2 million, or 76% of net sales, from $41.0 million, or 61% of net sales. Research and development (R&D) expenses raised to $7.8 million from $5.8 million for the fiscal 2014 second quarter. Selling, general and administrative (SG&A) expenses were $12.8 million, contrast with $9.9 million in the same quarter of the preceding year. Operating revenue more than doubled to $66.5 million from $25.4 million for the preceding year second quarter. Net revenue attributable to Lannett Company grew 170% to $44.8 million, or $1.21 per diluted share, from $16.6 million, or $0.46 per diluted share.
With recent incline, the year-to-date (YTD) performance reflected a 28.47% incline below last year. During the past month the stock gained 20.78%, bringing three-month performance to 8.04% and six-month performance to 56.77%. For this company, beta value at 1.26 represents it is more volatile to the shift in the market.
Lannett Company, Inc. (NYSE:LCI), develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States.
